Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2419]

ASCO 2026: Lung cancer roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

ASCO 2026: Lung cancer roundup ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Gedatolisib combinations double PFS vs alpelisib in PIK3CA-mutant advanced...

Dr Sara Hurvitz - Fred Hutchinson Cancer Center, Seattle, USA

Gedatolisib combinations double PFS vs alpelisib in PIK3CA-mutant advanced breast cancer ( Dr Sara Hurvitz - Fred Hutchinson Cancer Center, Seattle, USA )

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Velzatinib demonstrates broad activity across KIT mutations in advanced...

Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston...

Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours ( Dr Neeta Somaiah - The University of Texas MD Anderson Cancer Center, Houston, USA )

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type...

Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain

Optimal panitumumab–bevacizumab sequencing evaluated in RAS wild-type metastatic colorectal cancer ( Dr Ramón Salazar - The University of Barcelona, Barcelona, Spain )

Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer

Dr Lucy Gilbert - McGill University Health Centre, Montreal, Canada

Relacorilant chemo combination extends OS in platinum-resistant ovarian cancer ( Dr Lucy Gilbert - McGill University Health Centre, Montreal, Canada )

Aspirin in stage III colorectal cancer shows no significant DFS benefit but...

Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety ( Dr Atsuo Takashima - National Cancer Center Hospital, Tokyo, Japan )

ASCO 2026: Latest in prostate cancer

Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel...

ASCO 2026: Latest in prostate cancer ( Prof Eleni Efstathiou, Prof Boris Hadaschik, Dr Mary-Ellen Taplin and Prof Axel Merseburger )

Amivantamab in HPV-unrelated mHNSCC gives high response rates after...

Dr Barbara Burtness - Yale Cancer Center, New Haven, USA

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo ( Dr Barbara Burtness - Yale Cancer Center, New Haven, USA )

Gene expression test guided therapy in ER+/HER2- early breast cancer allows...

Dr Robert Stein - University College London, London, UK

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission ( Dr Robert Stein - University College London, London, UK )

Tarlatamab in SCLC shows consistent survival and low immune toxicity across age...

Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA

Tarlatamab in SCLC shows consistent survival and low immune toxicity across age groups ( Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA )

Fedratinib improves spleen and symptom responses with promising survival...

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )

More from ecancer